IMVT-1402 in refractory rheumatoid arthritis achieved statistical significance in the Period 2 ACR20 response rate, with the 600mg group meeting key endpoints at week 28 on both ACR20 and ACR50 versus placebo.

A statement by 현대차증권 제약/바이오/의료기기 김현석. Statements are as reported by the cited publishers — not verified by DecisionGateway.

IMVT-1402의 난치성 류마티스관절염 Period 2 탑라인 결과 발표. IMVT-1402 600mg 투여군은 28주차 ACR20과 ACR50에서 모두 고용량군이 위약군 대비 통계적 유의성을 달성해 주요 평가지표 충족